一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。乳腺癌领域多项重磅研究即将公布，肿瘤瞭望带您提前速览摘要题目（文中时间均为北京时间）。
编者按：一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。乳腺癌领域多项重磅研究即将公布，肿瘤瞭望带您提前速览摘要题目（文中时间均为北京时间）。
6月3日——Oral Abstract Session
▌Breast Cancer—Local/Regional/Adjuvant
摘要号：LBA500
Phase III NATALEE trial of ribociclib+endocrine therapy as adjuvant treatment in patients with HR+/HER2−early breast cancer.
Ⅲ期NATALEE试验：瑞波西利+内分泌治疗作为HR+/HER2-早期乳腺癌患者的辅助治疗
讲者：Dennis J.Slamon，MD，PhD|David Geffen School of Medicine at University of California Los Angeles
摘要号：501
Efficacy and safety results by age in monarchE:Adjuvant abemaciclib combined with endocrine therapy(ET)in patients with HR+，HER2-，node-positive，high-risk early breast cancer(EBC).
monarchE研究中不同年龄患者的疗效和安全性结果：阿贝西利联合内分泌（ET）辅助治疗HR+、HER2-、淋巴结阳性、高危早期乳腺癌（EBC）患者
讲者：Erika P.Hamilton，MD|Sarah Cannon Research Institute，Tennessee Oncology
摘要号：502
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer:Analysis from the PENELOPE-B trial.
PENELOPE-B试验分析：新辅助化疗和手术后检测ctDNA可预测ER阳性和HER2阴性乳腺癌的早期复发
讲者：Nicholas C.Turner，MD，PhD|The Institue of Cancer Research，Royal Cancer Hospital
摘要号：503
Effects of ovarian ablation or suppression on breast cancer recurrence and survival:Patient-level meta-analysis of 14，993 pre-menopausal women in 25 randomized trials.
卵巢切除或卵巢抑制对乳腺癌复发和生存的影响：25项随机试验中14993名绝经前女性的患者水平荟萃分析
讲者：Richard G.Gray|University of Oxford
摘要号：504
Evaluation of PAM50 intrinsic subtypes and risk of recurrence(ROR)scores in premenopausal women with early-stage HR+breast cancer:A secondary analysis of the SOFT trial.
SOFT试验的二次分析：在早期HR+乳腺癌绝经前女性中评估PAM50内在亚型和复发风险（ROR）评分
讲者：Lauren Claire Brown，MBChB|Peter MacCallum Cancer Centre
摘要号：505
Association of tumor-infiltrating lymphocytes(TILs)with clinicopathologic characteristics and prognosis in young women with HR+/HER2-breast cancer(BC).
HR+/HER2-年轻女性乳腺癌（BC）患者肿瘤浸润淋巴细胞（TILs）与临床病理特征和预后的关系
讲者：Megan E Tesch，MD|Dana-Farber Cancer Institute
摘要号：LBA506
3-year invasive disease-free survival(iDFS)of the strategy-based，randomized phase II PHERGain trial evaluating chemotherapy(CT)de-escalation in human epidermal growth factor receptor 2-positive(HER2[+])early breast cancer(EBC).
基于策略的、随机2期PHERGain试验评估了人表皮生长因子受体2阳性（HER2+）早期乳腺癌（EBC）的化疗降阶梯治疗疗效。
讲者：Javier Cortes，MD，PhD|International Breast Cancer Center(IBCC)，Pangaea Oncology，Quiron Group，Barcelona，Spain，Medica Scientia Innovation Research(MEDSIR)，Barcelona，Spain，Universidad Europea de Madrid，Faculty of Biomedical and Health Sciences，Department of Medicine
摘要号：507
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer(TNBC):Biomarker analysis of the NeoPACT trial.
NeoPACT试验生物标志物分析：增殖特征对sTIL高表达和sTIL低表达三阴性乳腺癌（TNBC）新辅助化学免疫疗法疗效的不同影响
讲者：Shane R Stecklein，MD|University of Kansas Medical Center
摘要号：508
Do tumor infiltrating lymphocytes(TILs)predict benefits from trastuzumab therapy for HER2 positive breast cancer?Meta-analysis of individual patient data from 4097 women in 5 trials.
5项试验4097例女性个体患者数据荟萃分析：肿瘤浸润淋巴细胞（TILs）能否预测曲妥珠单抗治疗HER2阳性乳腺癌的获益
讲者：Robert Kerrin Hills，MA MSc DPhil|University of Oxford
6月4日——Education Session
▌ASCO Plenary Series:Rapid Abstract Updates
390216摘要更新：
Adjuvant Palbociclib for ER+Breast Cancer(PALLAS Trial(ABCSG-42/AFT-05/PrE0109/BIG-14-13):A Preplanned Analysis of the Stage IIA Cohort.
哌柏西利辅助治疗ER+乳腺癌：PALLAS试验（ABCSG-42/AFT-05/PrE0109/BIG-14-13）ⅡA期队列的预设分析结局
讲者：Angela DeMichele，MD，MSCE|University of Pennsylvania
390226摘要更新：
Mepitel Film for the prevention of acute radiation dermatitis in breast cancer:A randomized multi-centre open-label phase 3 trial
Mepitel薄膜用于预防乳腺癌急性放射性皮炎：一项随机、多中心、开放标签的3期试验
讲者：Edward Chow，MBBS|Odette Cancer Centre，Sunnybrook Health Sciences Centre
6月4日——Rapid Abstract Session（Breast Cancer）
摘要号：509
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage，HR+breast cancer in the TEAM trial.
TEAM试验中，使用乳腺癌指数（Breast Cancer Index）评估早期HR+乳腺癌的绝经后女性的总体复发风险和晚期远处复发风险
讲者：John MS Bartlett，PhD|Cancer Research UK Scotland Centre，University of Edinburgh
摘要号：510
Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer(TNBC):A population-based study.
一项基于人群的研究：ⅠA期三阴性乳腺癌（TNBC）患者化疗使用的预后和趋势
讲者：Paolo Tarantino，MD|Dana-Farber Cancer Institute
摘要号：511
Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.
雌激素受体阳性乳腺癌患者21基因复发评分和生存的种族/民族差异
讲者：Jasmin Gill|University at Buffalo，The State University of New York
摘要号：512
A randomized controlled trial of a mobile app and tailored messages to improve outcomes among women with breast cancer receiving adjuvant endocrine therapy.
在一项随机对照试验中，使用移动应用程序和定制信息改善接受辅助内分泌治疗的女性乳腺癌患者的结局。
讲者：Ilana Graetz，PhD|Emory University，Rollins School of Public Health
摘要号：LBA1013
TORCHLIGHT:A randomized，double-blind，phase III trial of toripalimab versus placebo，in combination with nab-paclitaxel(nab-P)for patients with metastatic or recurrent triple-negative breast cancer(TNBC).
TORCHLIGHT：一项特瑞普利单抗对比安慰剂联合白蛋白紫杉醇（nab-P）用于转移性或复发性三阴性乳腺癌（TNBC）患者的随机、双盲、III期试验
讲者：江泽飞（解放军总医院第五医学中心）
摘要号：LBA637
Nine-weeks versus one-year trastuzumab for early-stage HER2+breast cancer:10-year update of the Short-HER phase III randomized trial.
Ⅲ期随机Short-HER试验10年更新结果：曲妥珠单抗治疗早期HER2+乳腺癌9周和1年比较
讲者：Pier Franco Conte，MD|Department of Surgery，Oncology and Gastroenterology，University of Padua，and Veneto Institute of Oncology IOV-IRCCS
6月4日——Poster Session
▌Breast Cancer—Local/Regional/Adjuvant
摘要号：LBA612|Poster Bd#:442
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage，high-risk breast cancer:Results from the neoadjuvant ISPY 2 TRIAL.
ISPY 2试验结果：新辅助治疗中口服紫杉醇和多司他利单抗联合或不联合曲妥珠单抗治疗早期高危乳腺癌
讲者：Rebecca Arielle Shatsky，MD|University of California San Diego Medical Center
6月4日——Poster Session
▌Breast Cancer—Metastatic
摘要号：LBA1068|Poster Bd#:289
Palbociclib(P)plus tamoxifen(TAM)±goserelin in women with hormone receptor-positive(HR+)/HER2-negative(HER2−)advanced breast cancer(ABC):Primary results of NCCH1607/PATHWAY，an Asian international double-blind randomized phase 3 trial.
NCCH1607/PATHWAY亚洲国际双盲随机3期试验：哌柏西利（P）联合他莫昔芬（TAM）±戈舍瑞林治疗HR+/HER2-晚期乳腺癌的主要结果
讲者：TAKAHIRO KOGAWA，MD，PhD|National Cancer Center Hospital East
摘要号：LBA520|Poster Bd#:350
Oral paclitaxel，carboplatin，and dostarlimab(OPE/Cb/D)without and with trastuzumab in early-stage，high-risk breast cancer:Results from the neoadjuvant I-SPY 2 TRIAL.
I-SPY 2试验的结果：口服紫杉醇、卡铂和多司他利（OPE/Cb/D）联合或不联合曲妥珠单抗新辅助治疗早期高危乳腺癌
讲者：Kay T Yeung，MD，PhD|University of California，San Diego
6月5日Poster Discussion Session
▌Breast Cancer—Metastatic
摘要号：1017|Poster Bd#:238
LEONARDA-1:Phase III randomized study of lerociclib plus fulvestrant in patients with HR+，HER2-locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
LEONARDA-1：Ⅲ期随机对照研究，lerociclib联合氟维司群治疗既往内分泌治疗进展的HR+/HER2-局部晚期或转移性乳腺癌患者。
讲者：徐兵河（中国医学科学院肿瘤医院）
6月6日——Oral Abstract Session
▌Breast Cancer—Metastatic
摘要号：LBA1000
Primary outcome analysis of the phase 3 SONIA trial(BOOG 2017-03)on selecting the optimal position of cyclin-dependent kinases 4 and 6(CDK4/6)inhibitors for patients with hormone receptor-positive(HR+)，HER2-negative(HER2-)advanced breast cancer(ABC).
3期SONIA试验（BOOG 2017-03）初步结果分析：激素受体阳性（HR+）、HER2阴性（HER2-）晚期乳腺癌（ABC）患者选择CDK4/6抑制剂的最佳时机。
讲者：Gabe S.Sonke，MD，PhD|The Netherlands Cancer Institute
摘要号：1001
Second-line endocrine therapy(ET)with or without palbociclib(P)maintenance in patients(pts)with hormone receptor-positive(HR[+])/human epidermal growth factor receptor 2-negative(HER2[-])advanced breast cancer(ABC):PALMIRA trial.
PALMIRA试验：HR+/HER2-晚期乳腺癌（ABC）患者（pts）内分泌治疗（ET）联合或不联合哌柏西利（P）进行二线维持治疗
讲者：Antonio Llombart-Cussac，MD|Hospital Arnau de Vilanova，Universidad Católica de Valencia，Medica Scientia Innovation Research(MEDSIR)，Barcelona
摘要号：1002
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.
在PADA-1试验中，随机分组后，芳香化酶抑制剂或氟维司群联合哌柏西利治疗下的ESR1突变动力学和类型
讲者：Francois Clement Bidard，MD，PhD|Institut Curie
摘要号：1003
Final overall survival(OS)analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan(SG)in patients(pts)with hormone receptor–positive/HER2-negative(HR+/HER2–)metastatic breast cancer(mBC).
Ⅲ期TROPiCS-02研究的最终总生存期分析：戈沙妥珠单抗（SG）治疗HR+/HER2-转移性乳腺癌
讲者：Sara M.Tolaney，MD，MPH|Department of Medical Oncology，Dana-Farber Cancer Institute
摘要号：1004
A phase 2 study of HER3-DXd in patients(pts)with metastatic breast cancer(MBC).
HER3-DXd治疗转移性乳腺癌的2期临床研究
讲者：Erika P.Hamilton，MD|Sarah Cannon Research Institute，Tennessee Oncology，PLLC
摘要号：1005
Dynamic HER2-low status among patients with triple negative breast cancer(TNBC):The impact of repeat biopsies.
三阴性乳腺癌（TNBC）患者中动态HER2低表达状态：重复活检的影响
讲者：Yael Bar，MD，PhD|Massachusetts General Hospital
摘要号：1006
An age-specific pooled analysis of trastuzumab deruxtecan(T?DXd)in patients(pts)with HER2-positive(HER2+)metastatic breast cancer(mBC)from DESTINY-Breast01，-02，and-03.
DESTINY-Breast01、DESTINY-Breast02和DESTINY-Breast03研究中T-DXd治疗HER2阳性（HER2+）转移性乳腺癌（mBC）患者（pts）的年龄特异性汇总分析
讲者：Ian E.Krop，MD，PhD|Yale Cancer Center
摘要号：1007
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer:The X-7/7 trial.
X-7/7试验：固定剂量卡培他滨与标准剂量卡培他滨治疗转移性乳腺癌的随机对照试验
讲者：Qamar J.Khan，MD|University of Kansas Cancer Center
摘要号：1008
CANKADO PRO-React eHealth support in patients with HR+HER2-metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life:Primary outcome analysis of the multicenter randomized PreCycle trial.
PreCycle多中心随机试验的主要结局分析：电子健康支持系统（CANKADO PRO-React）在接受哌柏西利和内分泌治疗的HR+/HER2-转移性乳腺癌患者中的应用及其对生活质量恶化时间的影响。
讲者：Nadia Harbeck，MD，PhD|Breast Center，Department of Obstetrics and Gynecology and CCC Munich，LMU University Hospital
京公网安备 11010502033352号